InMed Pharmaceuticals (INM)
NASDAQ:INM
Top Page
InMed Pharmaceuticals
(NASDAQ:INM)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.63
▼(-43.84% Downside)
Action:ReiteratedDate:03/31/26
The score is weighed down primarily by weak financial fundamentals (large ongoing losses and cash burn despite improving revenue) and bearish technicals (below all key moving averages with negative MACD). Corporate events are mixed but include meaningful listing and business-transition risk, while valuation inputs are not meaningful/supportive based on the provided P/E and missing dividend yield.
Positive Factors
Low leverage / balance-sheet strength
Very low debt-to-equity across reported periods gives InMed structural financial flexibility. Limited leverage reduces bankruptcy and refinancing risk, enabling the company to prioritize R&D and regulatory milestones without heavy interest burdens, a durable advantage for a clinical-stage biotech.
Negative Factors
Persistent cash burn and weak cash generation
Repeated negative operating cash flow and sizable free-cash-flow deficits create structural funding pressure for a clinical-stage biotech. Limited cash on hand and high burn require ongoing external financing, risking dilution and constraining long-term program execution if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance-sheet strength
Very low debt-to-equity across reported periods gives InMed structural financial flexibility. Limited leverage reduces bankruptcy and refinancing risk, enabling the company to prioritize R&D and regulatory milestones without heavy interest burdens, a durable advantage for a clinical-stage biotech.
Read all positive factors
InMed Pharmaceuticals (INM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.99M
Dividend YieldN/A
Average Volume (3M)113.41K
Price to Earnings (P/E)―
Beta (1Y)3.39
Revenue Growth-3.27%
EPS Growth51.83%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.51
Shares Outstanding2,919,186
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap-3.82
Enterprise Value/Revenue-1.44
Enterprise Value/Gross Profit-5.42
Enterprise Value/Ebitda0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
InMed Pharmaceuticals Business Overview & Revenue Model
Company Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treat...
How the Company Makes Money
InMed Pharmaceuticals primarily funds its operations through external financing rather than recurring product revenue. The company has historically generated cash mainly by issuing equity and equity-linked securities (e.g., common shares, warrants...
InMed Pharmaceuticals Key Performance Indicators (KPIs)
InMed Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
16
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.28M | 4.94M | 4.60M | 4.14M | 1.09M | 0.00 |
| Gross Profit | 1.40M | 1.71M | 1.10M | 1.40M | 543.55K | 0.00 |
| EBITDA | -8.69M | -7.26M | -7.06M | -7.78M | -13.28M | -12.17M |
| Net Income | -9.07M | -8.16M | -7.68M | -7.95M | -18.60M | -12.65M |
Balance Sheet | ||||||
| Total Assets | 15.36M | 21.23M | 16.17M | 18.69M | 16.46M | 12.10M |
| Cash, Cash Equivalents and Short-Term Investments | 9.60M | 15.09M | 8.99M | 11.81M | 8.01M | 9.16M |
| Total Debt | 730.14K | 1.01M | 1.32M | 518.92K | 1.02M | 333.64K |
| Total Liabilities | 2.20M | 2.92M | 3.58M | 2.67M | 4.78M | 2.97M |
| Stockholders Equity | 13.16M | 18.30M | 12.59M | 16.02M | 11.69M | 9.12M |
Cash Flow | ||||||
| Free Cash Flow | -8.91M | -7.77M | -7.00M | -7.45M | -15.62M | -9.79M |
| Operating Cash Flow | -8.91M | -7.77M | -6.99M | -7.28M | -15.58M | -9.79M |
| Investing Cash Flow | 0.00 | 0.00 | -9.29K | -661.80K | -673.00K | -1.73K |
| Financing Cash Flow | 10.90M | 12.27M | 4.65M | 10.68M | 15.07M | 10.85M |
InMed Pharmaceuticals Technical Analysis
Negative
1.12
Price Trends
0.86
Negative
1.07
Negative
1.72
Negative
Market Momentum
-0.06
Negative
38.67
Neutral
61.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INM, the sentiment is Negative. The current price of 1.12 is above the 20-day moving average (MA) of 0.75, above the 50-day MA of 0.86, and below the 200-day MA of 1.72, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 38.67 is Neutral, neither overbought nor oversold. The STOCH value of 61.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INM.
InMed Pharmaceuticals Risk Analysis
InMed Pharmaceuticals disclosed 82 risk factors in its most recent earnings report. InMed Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InMed Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $1.99M | ― | -82.17% | ― | -3.27% | 51.83% | |
| ― | $6.94M | -1.51 | -167.97% | ― | ― | 68.59% | |
50 Neutral | $7.33M | -1.38 | -60.33% | ― | 13.30% | 22.70% | |
46 Neutral | $5.34M | ― | -386.72% | ― | 1.51% | 77.64% |
* Healthcare Sector Average
INM
InMed Pharmaceuticals
0.68
-1.57
-69.75%
TCRT
Alaunos Therapeutics
2.92
0.41
16.33%
XBIO
Xenetic Biosciences
3.20
0.90
39.13%
ENSC
Ensysce Biosciences
0.58
-1.28
-69.03%
KTTA
Pasithea Therapeutics Corp
0.80
-0.39
-32.94%
InMed Pharmaceuticals Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance
Negative
Mar 30, 2026
On March 27, 2026, InMed Pharmaceuticals disclosed it had received a Nasdaq notification that its common shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive trading days between February 11 and March 26, 2026. The comp...
Business Operations and StrategyProduct-Related Announcements
InMed Reports Positive Preclinical Data for Alzheimer’s Candidate
Positive
Mar 23, 2026
On March 23, 2026, InMed Pharmaceuticals reported positive preclinical data showing its INM-901 candidate significantly reduced neuroinflammation in advanced 3D human brain organoid models of Alzheimer’s disease. The results, generated with ...
Business Operations and StrategyProduct-Related Announcements
InMed outlines 2026 development plans for lead programs
Positive
Mar 9, 2026
On March 9, 2026, InMed outlined its 2026 pharmaceutical development outlook, highlighting significant 2025 preclinical progress for lead Alzheimer’s candidate INM-901, including reduced inflammatory and neurodegenerative biomarkers, evidenc...
Business Operations and StrategyFinancial Disclosures
InMed Pharmaceuticals Exits BayMedica to Refocus on Pipeline
Negative
Mar 6, 2026
InMed Pharmaceuticals said that on March 4, 2026, its board ratified BayMedica LLC’s decision to wind down and exit its commercial operations in rare, non-intoxicating cannabinoids before the end of the fiscal year ending June 30, 2026, in r...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
InMed Highlights Q2 Results Amid Cash, Regulatory Pressures
Negative
Feb 12, 2026
On February 11, 2026, InMed reported second-quarter fiscal 2026 results for the period ended December 31, 2025, highlighting progress in its neurology and ophthalmology programs while managing a tightening cash position. The company completed key ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.